Know Cancer

or
forgot password

    • cancer clinical trials in kansas city, KS

    • Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lung Cancer
    A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    Trial of Decitabine in Patients With Acute Myeloid Leukemia

    Kansas City, Kansas 66160
    Acute Myeloid Leukemia
    A Long-term Safety Study of Infliximab (Remicade)

    Kansas City, Kansas 66160
    Arthritis, Rheumatoid, Crohn Disease, Psoriasis
    Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Recurrent Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Head and Neck Cancer
    Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
    Kansas City Cancer Center
    Kansas City, Kansas 66112
    Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma
    Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
    University of Kansas Medical Center

    Trial Locations
    University of Kansas Medical Center
    Providence Medical Center
    Recurrent Melanoma, Stage IV Melanoma
    Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

    Kansas City, Kansas 66160
    B-cell Acute Lymphoblastic Leukemia
    Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    Protocol for Women at Increased Risk of Developing Breast Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    Protocol for Women at Increased Risk of Developing Breast Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009)
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
    PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
    Providence Medical Center
    Kansas City, Kansas 66112
    Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
    A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Acute Myelogenous Leukemia
    A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Oral Mucositis, Stomatitis
    A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Multiple Sclerosis
    A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
    University Of Kansas
    Kansas City, Kansas 66160
    Carcinoma, Non-Small-Cell Lung
    High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Sarcoma
    Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
    GSK Investigational Site
    Kansas City, Kansas 66160
    Neoplasms, Prostate, Prostate Cancer
    Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Graft Versus Host Disease
    Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
    GSK Investigational Site
    Kansas City, Kansas 66160
    Human Papillomavirus Type-16/-18 Infection, Papillomavirus Vaccines, Cervical Neoplasia
    A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
    Veterans Affairs Medical Center
    Kansas City, Kansas 64128
    Tumors
    Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
    Pfizer Investigational Site
    Kansas City, Kansas 66112
    Thyroid Neoplasms
    Diindolylmethane in Healthy Volunteers
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Unspecified Adult Solid Tumor, Protocol Specific
    Expanded Access Program for Maraviroc At Multiple Centers
    Pfizer Investigational Site
    Kansas City, Kansas 66112
    Advanced HIV Infection
    S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Prostate Cancer
    Disease Management for Smoking Cessation
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Smoking Cessation
    Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Lung Cancer, Colorectal Cancer, Head and Neck Cancer
    Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
    Pfizer Investigational Site
    Kansas City, Kansas 66112
    Colorectal Neoplasms
    cRisk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Leukemia
    Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Multiple Sclerosis, Relapsing-Remitting
    A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Multiple Myeloma
    Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Multiple Sclerosis, Relapsing-Remitting
    A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
    Kansas Masonic Cancer Research Center
    Kansas City, Kansas 66160
    Advanced Cancer, Refractory Cancer
    An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Pancreatic Cancer
    Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Head and Neck Cancer, Carcinoma, Squamous
    Use of Novel Tailored Reminders in Rural Primary Care
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Colorectal Cancer
    "Touch 2 Screen" Multi-media Colorectal Cancer Screening Intervention
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Colorectal Cancer
    Use of a Radiolucent Pad to Reduce Mammography Among African Americans
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Breast Cancer
    Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Prostate Cancer
    Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
    Pfizer Investigational Site
    Kansas City, Kansas 66112
    Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
    Multi-day Doses in Prevention of Nausea and Emesis
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Myeloma, Plasma-Cell, Lymphoma, Malignant
    Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
    University of Kansas Cancer Center
    Kansas City, Kansas 66160
    Non-small Cell Lung Cancer
    Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
    Pfizer Investigational Site
    Kansas City, Kansas 66112
    Colorectal Neoplasms
    Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
    Sanofi-Aventis Investigational Site Number 840054
    Kansas City, Kansas 66160-7321
    Urinary Bladder Neoplasms
    A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
    University of Kansas Cancer Center
    Kansas City, Kansas 66160
    Metastatic Melanoma
    Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Severe Sepsis
    Surgical Versus Nonoperative Treatment of Metastatic Epidural Spinal Cord Compression
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Metastatic Epidural Spinal Cord Compression
    A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
    Site Reference ID/Investigator# 24483
    Kansas City, Kansas 66160
    Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Neoplasm Metastasis, Nervous System Neoplasms
    Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
    Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Head and Neck Cancer
    Follow-Up Study for Exubera
    Pfizer Investigational Site
    Kansas City, Kansas 66112
    Diabetes Mellitus
    A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
    University of Kansas Medical Center
    Kansas City, Kansas 66160-7353
    Non-Small Cell Lung Cancer